-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics. In 2025, there were 308.98 million 12- month total diagnosed prevalent cases of GERD in the 16 countries covered in GlobalData’s epidemiology forecast. The management of GERD typically includes a mix of lifestyle adjustments, medication-based treatments, and, in certain cases, surgical or procedural options. Key therapy classes showing this effect include PPIs, histamine H2 receptor (HRH2) antagonists, and dopamine receptor...
-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Hepatocellular carcinoma (HCC) arises from the hepatocyte cells in the liver and is the most common primary liver cancer, accounting for approximately 90% of all primary cancers of the liver (Asafo-Agyei and Samant, 2023). HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide (Singal, Kanwal and Llovet, 2023). Major risk factors for HCC include infection with the hepatitis B virus (HBV), infection with the hepatitis C virus (HCV), and high alcohol consumption...
-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Obesity is a chronic disease characterized by the accumulation of excess body fat. Individuals living with obesity may undergo metabolic dysfunction on account of excess adipose tissue. The diagnostic criteria for obesity are met by a body mass index (BMI) of 30kg/m2 or more (NIH, 2022a). This can lead to a state of chronic systemic inflammation, as well as a predisposition to comorbidities such as diabetes and cardiovascular disease. Clinical interventions aim to manage obesity by encouraging patient behavioral change,...
-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...
-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Epilepsy is a neurological condition defined by repeated, unpredictable seizures resulting from abrupt, chaotic, and intense electrical activity among brain cells (World Health Organization, 2024a). Globally, it ranks as one of the most widespread neurological disorders (World Health Organization, 2024a). This chronic condition can develop at any point in a person's life. A diagnosis typically occurs after an individual experiences at least one seizure and sees a specialist, who evaluates detailed accounts of both the pre-seizure warning signs and the...
-
Company Insights
Catalyst Monitor: Q3 2026 Outlook
This report compiles published, predictive intelligence based on interviews with key opinion leaders (KOLs) on market-moving events that are expected to occur in Q3 2026. GlobalData’s latest report, “Catalyst Monitor Q3 2026”, delivers forward-looking intelligence derived from interviews with key opinion leaders (KOLs), covering trial initiations, completions, Phase III trial results, PDUFA dates, and regulatory filings. The report covers 11 significant catalyst events that are expected to occur in Q3 2026. Some of the catalysts covered in the report, include...
-
Sector Analysis
New Drug Approvals and Their Contract Manufacture: 2026 Edition
This report is the 16th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how the US onshoring push is creating billion-dollar manufacturing investments.
-
Thematic Analysis
State of the Biopharmaceutical Industry 2026 (Mid-Year Update) Edition
Report Value Proposition – Why This Matters for You The biopharmaceutical industry enters 2026 facing a rapidly evolving landscape shaped by artificial intelligence adoption, regulatory changes, pricing pressures, geopolitical uncertainty, and increasing competition for innovation leadership. This report helps stakeholders understand the trends that will define biopharma performance over the next 12 months, covering R&D productivity, commercialization strategies, market access challenges, investment sentiment, and emerging growth opportunities. Drawing on industry surveys, proprietary market intelligence, and expert analyst insight, the report...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, May 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics. In 2025, there were more than 5.15 million diagnosed incident cases of nasal polyps and CRSwNP in the 16 countries covered in GlobalData’s epidemiology forecast. The current treatment landscape for nasal polyps primarily involves intranasal corticosteroids, oral corticosteroids for severe cases, and functional endoscopic sinus surgery for patients unresponsive to medical therapy, with biologics...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.